- Home
- UTHR vs MNDY Comparison
UTHR vs MNDY Comparison
Compare UTHR & MNDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- MNDY
- Stock Information
- Founded
- UTHR 1996
- MNDY 2012
- Country
- UTHR United States
- MNDY Israel
- Employees
- UTHR N/A
- MNDY N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- MNDY Computer Software: Prepackaged Software
- Sector
- UTHR Health Care
- MNDY Technology
- Exchange
- UTHR Nasdaq
- MNDY Nasdaq
- Market Cap
- UTHR 14.4B
- MNDY 12.0B
- IPO Year
- UTHR 1999
- MNDY 2021
- Fundamental
- Price
- UTHR $306.97
- MNDY $247.01
- Analyst Decision
- UTHR Buy
- MNDY Strong Buy
- Analyst Count
- UTHR 12
- MNDY 23
- Target Price
- UTHR $388.25
- MNDY $351.65
- AVG Volume (30 Days)
- UTHR 492.5K
- MNDY 822.4K
- Earning Date
- UTHR 04-30-2025
- MNDY 05-14-2025
- Dividend Yield
- UTHR N/A
- MNDY N/A
- EPS Growth
- UTHR 24.38
- MNDY N/A
- EPS
- UTHR 24.64
- MNDY 0.62
- Revenue
- UTHR $2,877,400,000.00
- MNDY $971,995,000.00
- Revenue This Year
- UTHR $11.70
- MNDY $27.78
- Revenue Next Year
- UTHR $6.50
- MNDY $24.15
- P/E Ratio
- UTHR $12.40
- MNDY $398.40
- Revenue Growth
- UTHR 23.63
- MNDY 33.21
- 52 Week Low
- UTHR $221.53
- MNDY $174.75
- 52 Week High
- UTHR $417.82
- MNDY $342.64
- Technical
- Relative Strength Index (RSI)
- UTHR 39.02
- MNDY 40.80
- Support Level
- UTHR $308.43
- MNDY $257.96
- Resistance Level
- UTHR $318.40
- MNDY $281.86
- Average True Range (ATR)
- UTHR 9.26
- MNDY 10.66
- MACD
- UTHR 1.20
- MNDY -0.33
- Stochastic Oscillator
- UTHR 29.88
- MNDY 30.10
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About MNDY monday.com Ltd.
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.